Dunlop Boadie W, Rajendra Justin K, Craighead W Edward, Kelley Mary E, McGrath Callie L, Choi Ki Sueng, Kinkead Becky, Nemeroff Charles B, Mayberg Helen S
From the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta; the Department of Psychology, Emory University, Atlanta; the Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta; the Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, Mass.; and the Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami.
Am J Psychiatry. 2017 Jun 1;174(6):533-545. doi: 10.1176/appi.ajp.2016.16050518. Epub 2017 Mar 24.
The purpose of this article was to inform the first-line treatment choice between cognitive-behavioral therapy (CBT) or an antidepressant medication for treatment-naive adults with major depressive disorder by defining a neuroimaging biomarker that differentially identifies the outcomes of remission and treatment failure to these interventions.
Functional MRI resting-state functional connectivity analyses using a bilateral subcallosal cingulate cortex (SCC) seed was applied to 122 patients from the Prediction of Remission to Individual and Combined Treatments (PReDICT) study who completed 12 weeks of randomized treatment with CBT or antidepressant medication. Of the 122 participants, 58 achieved remission (Hamilton Depression Rating Scale [HAM-D] score ≤7 at weeks 10 and 12), and 24 had treatment failure (<30% decrease from baseline in HAM-D score). A 2×2 analysis of variance using voxel-wise subsampling permutation tests compared the interaction of treatment and outcome. Receiver operating characteristic curves constructed using brain connectivity measures were used to determine possible classification rates for differential treatment outcomes.
The resting-state functional connectivity of the following three regions with the SCC was differentially associated with outcomes of remission and treatment failure to CBT and antidepressant medication and survived application of the subsample permutation tests: the left anterior ventrolateral prefrontal cortex/insula, the dorsal midbrain, and the left ventromedial prefrontal cortex. Using the summed SCC functional connectivity scores for these three regions, overall classification rates of 72%-78% for remission and 75%-89% for treatment failure was demonstrated. Positive summed functional connectivity was associated with remission with CBT and treatment failure with medication, whereas negative summed functional connectivity scores were associated with remission to medication and treatment failure with CBT.
Imaging-based depression subtypes defined using resting-state functional connectivity differentially identified an individual's probability of remission or treatment failure with first-line treatment options for major depression. This biomarker should be explored in future research through prospective testing and as a component of multivariate treatment prediction models.
本文旨在通过定义一种神经影像生物标志物,为首次接受治疗的重度抑郁症成年患者在认知行为疗法(CBT)和抗抑郁药物之间的一线治疗选择提供参考,该生物标志物能够区分这两种干预措施的缓解和治疗失败结果。
对来自“个体及联合治疗缓解预测”(PReDICT)研究的122例患者进行静息态功能磁共振成像(fMRI)静息态功能连接分析,这些患者完成了为期12周的CBT或抗抑郁药物随机治疗。在这122名参与者中,58人实现缓解(第10周和第12周汉密尔顿抑郁量表[HAM-D]评分≤7),24人治疗失败(HAM-D评分较基线下降<30%)。使用体素级子采样置换检验进行的2×2方差分析比较了治疗与结果的相互作用。利用脑连接测量构建的受试者工作特征曲线来确定不同治疗结果的可能分类率。
以下三个区域与胼胝体下扣带回皮质(SCC)的静息态功能连接与CBT和抗抑郁药物的缓解和治疗失败结果存在差异关联,并且在子样本置换检验中得以保留:左侧前外侧前额叶皮质/脑岛、背侧中脑和左侧腹内侧前额叶皮质。使用这三个区域的SCC功能连接分数总和,缓解的总体分类率为72%-78%,治疗失败的总体分类率为75%-89%。正的功能连接分数总和与CBT缓解和药物治疗失败相关,而负的功能连接分数总和与药物缓解和CBT治疗失败相关。
使用静息态功能连接定义的基于影像的抑郁症亚型能够不同程度地识别个体在重度抑郁症一线治疗方案中的缓解或治疗失败概率。这种生物标志物应在未来研究中通过前瞻性测试进行探索,并作为多变量治疗预测模型的一个组成部分。